Sudarshan Q1FY27: consolidated PAT up 88% YoY to ₹103 Cr as margins expand, revenue +5%
PAT +88% YoY · revenue +5.4% · margins expanding
₹2,642.1 Cr
+5.4% YoY
₹103.4 Cr
+88% YoY
3.89%
+1.7pp YoY
₹12.3
Sudarshan Chemical's consolidated (primary basis) Q1 FY27 profit for the quarter rose to ₹103.4 Cr from ₹55.0 Cr a year ago (+88% YoY; owners' share ₹97.3 Cr vs ₹47.2 Cr, +106%), on revenue of ₹2,642.1 Cr, up a modest 5.4% YoY but down 5.3% QoQ from ₹2,789.9 Cr — the QoQ dip is a sequential normalisation off a strong March-quarter order push rather than a fresh demand signal, and is not the headline here since YoY is the primary read. Net margin expanded to ~3.9% from 2.2% a year ago, and segment EBITDA margin (per the Part II disclosure) improved to ~9.8% (₹258.8 Cr) from 7.7% (₹192.4 Cr), helped by cost of materials falling to ~51.6% of revenue from ~54.9% and a ₹6.1 Cr higher joint-venture profit contribution (₹13.2 Cr vs ₹7.1 Cr). No exceptional items hit either period, so reported and adjusted growth are the same — but the print absorbed ₹36.1 Cr of Heubach-related integration and restructuring costs embedded in opex, meaning underlying margin progress would look even stronger excluding that drag.
Q1 FY-2027 vs prior quarters
The standalone (India-only) entity tells a different story and the divergence is material: standalone revenue actually grew faster than consolidated at 27.5% YoY (₹677.4 Cr vs ₹531.2 Cr), yet standalone PAT fell 21% YoY to ₹57.8 Cr from ₹73.3 Cr. The gap is explained by a ₹62.6 Cr unfavourable foreign-exchange swing embedded in other expenses (a ₹5.7 Cr loss this quarter versus a ₹56.9 Cr gain in the year-ago quarter) — stripping that swing out, standalone opex growth (~19%) tracked broadly with revenue growth. Readers comparing the two statements should treat consolidated as the operative number; the standalone decline is a forex-timing effect, not a demand or cost-structure deterioration.
The stock went into the print at ₹1,044.7, down 2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.
Management projects an EBITDA of $35 million for the next financial year, driven by ongoing integration synergies and value capture initiatives. The company expects to achieve $90-100 million in EBITDA over the next 3-4 years, as previously guided at the time of acquisition. While near-term demand is viewed cautiously
On guidance: management's last concall projected Heubach EBITDA of $35 million for FY27 and $90-100 million over 3-4 years, with near-term demand described as cautiously watched given geopolitical uncertainty; this filing does not break out Heubach-specific quarterly EBITDA (only Pigments/Others segments are disclosed), so progress against that specific target cannot be verified from the statement itself — treated as unknown rather than assumed met. No management press release or commentary beyond the regulatory board-outcome letter was available for this filing, and no analyst consensus figure for this specific quarter's revenue or PAT could be sourced, so the print is also unscored against Street. Alongside results, the Board also approved in-principle internal restructuring to directly acquire the Company's existing 70.26% indirect stake in Sudarshan Colorants India Limited (formerly Heubach Colorants India) from intermediate Europe/Switzerland holding entities — a related-party, arm's-length, cash-funded reorganisation with no announced price or timeline and no control or operational impact, so no P&L effect this quarter.
W1
Trajectory of the ₹36.1 Cr Heubach integration/restructuring costs embedded in this quarter's opex — watch whether this fades as management's $35 million FY27 EBITDA synergy target for Heubach progresses
W2
A wholly-owned subsidiary entered an employee restructuring agreement after 30 June 2026 (per note 9); consolidated impact is unassessed and could add further one-off costs in Q2
W3
Standalone forex exposure — this quarter's ₹62.6 Cr unfavourable YoY swing was the main drag on standalone PAT; monitor whether currency moves reverse or persist
Watch for margin recovery as Heubach integration matures
After absorbing integration costs in FY26, Sudarshan Chemical faces Q1 as the test of whether operating leverage from the consolidated business is flowing through. Street expects 15-20% PAT growth in FY27; the quarterly print will signal how far margin recovery has come.
The setup
Sudarshan Chemical's Q1 FY27 result lands on a critical juncture: after a year of intentional margin compression to integrate the Heubach Group and absorb customer-retention costs, the Street is watching for signals that operating leverage is beginning to flow through. Analyst consensus expects 15–20% PAT growth for FY27 as a whole, but that number is only real if Q1 shows momentum in EBITDA margins and gross-profit discipline from the unified business.
What to expect
~₹2,350 Cr
On-plan: steady-state run-rate from Heubach contribution + standalone growth. FY26 full-year was ₹9,787 Cr consolidated (₹3,346 Cr in FY25 pre-acquisition), implying quarterly base ~₹2,300–2,400 Cr.
Watch for stabilisation
On-plan: FY26 saw margin dip to 6.0% (₹590 Cr EBITDA on ₹9,787 Cr revenue) due to integration costs; early signs of payoff emerging. Q1 should show margin holding or modest recovery if integration discipline is working.
Double-digit yoy
FY27 guidance consensus: 15–20% PAT expansion. Q1 will signal whether this is credible; Street wants to see the cost base coming down and Heubach synergies flowing.
Integration complete; capital light ahead
Heubach acquisition closed March 2025. No major capex announced. One Sudarshan integration ongoing; Frankfurt HQ operational. Expect clean cash generation.
A strong Q1 would show EBITDA margin at or above 6.0–6.2%, revenue in the ₹2,350–2,450 Cr band, and PAT growth of 12–15% yoy, signalling that integration costs are winding down and pigment-business scale is working. A weak Q1 would flag margin compression below 5.8%, sluggish top-line growth (< 5% yoy), or PAT growth missing consensus, suggesting either integration drag persisting or customer pressure in standalone India business.
On track?
Yes, but with caveats. FY26 revenue more than doubled to ₹9,787 Cr on Heubach, but EBITDA margins compressed sharply as the company absorbed redundancy and customer-retention costs. This was deliberate and expected. What Street wants to see now is evidence that the cost base is normalising and that Sudarshan's cost-per-rupee-of-revenue is trending down. If Q1 shows margin holding or slight recovery, FY27 guidance (15–20% PAT growth) becomes credible. If margins stay under pressure, FY27 becomes a question mark.
What the Street says
Since last quarter
1 · Promoter warrant conversion (June 2026)
Rajesh Rathi, Global Chairman & MD, converted 9.8 lakh warrants into equity, raising his stake from 8.19% to 9.32%. This signals management confidence in the integration narrative and H2 outlook. Positive signal for near-term momentum.
2 · Frankfurt HQ inaugurated (June 2026)
Sudarshan opened its second global head office in Frankfurt, marking post-Heubach integration milestones. Symbol of integration progress and European footprint deepening. Operationally routine but strategically reinforcing.
3 · FY26 dividend: ₹5 per share (250% of face value)
Record date Aug 11, 2026 (today). Board recommended ₹5 dividend for FY26, unchanged from prior year payout despite margin compression in FY26. Signals board confidence in FY27 cash generation and no dividend cut fears.
4 · 75th AGM scheduled for Aug 18, 2026
Routine shareholder meeting post-result. No governance concerns flagged; BRSR filed. Normal. No insider trading window open until Aug 14.
Bottom line
Sudarshan Chemical is at an inflection point: the Heubach integration is 16 months in, cost absorption is winding down, and the Street is waiting for the unified business to prove it can deliver operating leverage. Q1 FY27 is the acid test. Watch for EBITDA margin recovery (from FY26's 6.0% toward 6.5%+), revenue run-rate confirmation (₹2,350+ Cr), and PAT growth that validates the 15–20% FY27 guidance. If margins are sticky at 5.8%–6.0% and PAT growth is in single digits, it signals integration drag persisting and Street targets may get reset down. A margin beat and top-line growth would confirm the bull case and likely drive the stock higher toward the ₹1,217–1,486 target band.